Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Attention-Deficit/Hyperactivity Disorder

In brief

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Key facts

Study ID

NCT00640185

Run by

AbbVie (prior sponsor, Abbott)

People needed

160

Starts

2008-03-01

Expected to finish

2008-08-01

Last updated by the study team

2013-01-18

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have voluntarily signed an informed consent form.
• Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on detailed evaluation and interview with subject.
• Subject is generally in good health based on medical history, physical examination, clinical lab tests and ECG.
• Female subjects of child-bearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements.
• Male subjects must agree to comply with applicable contraceptive requirements.
• Subject is able to keep required appointments for clinic visits and all tests, including blood draws and examinations.

You may not qualify if…

• Subject has a current or past diagnosis of schizoaffective disorder, schizophrenia, obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic disorder.
• Current diagnosis of major depressive disorder, generalized anxiety disorder, PTSD or has a sleep disorder requiring treatment of any kind.
• Subject has a history of, or ongoing, serious medical problem.
• Subject has a history of significant allergic reaction to any drug.
• Subject is planning to begin any type of behavioral or psychotherapy for treatment of ADHD.
• Subject requires ongoing treatment with any psychiatric medication.

Where it is running

• Site Reference ID/Investigator# 7546 — Lafayette, California, United States
• Site Reference ID/Investigator# 7551 — Jacksonville, Florida, United States
• Site Reference ID/Investigator# 7553 — Orlando, Florida, United States
• Site Reference ID/Investigator# 7545 — Overland Park, Kansas, United States
• Site Reference ID/Investigator# 7552 — Farmington Hills, Michigan, United States
• Site Reference ID/Investigator# 7548 — Troy, Michigan, United States
• Site Reference ID/Investigator# 7554 — Eugene, Oregon, United States
• Site Reference ID/Investigator# 7547 — Portland, Oregon, United States
• Site Reference ID/Investigator# 7555 — Memphis, Tennessee, United States
• Site Reference ID/Investigator# 7549 — Virginia Beach, Virginia, United States
• Site Reference ID/Investigator# 7550 — Bellevue, Washington, United States
• Site Reference ID/Investigator# 7631 — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.